Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00369395
Status:
TERMINATED
Last Update Posted:
2012-04-27
First Post:
2006-08-24
Brief Title:
A Study of Volociximab in Metastatic Melanoma
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Phase 2 Open-Label Two-Stage Study of Volociximab M200 for the Treatment of Subjects With Metastatic Melanoma
Status:
TERMINATED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Insufficient clinical activity
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 multicenter research study determining the effects of an investigational drug called volociximab in metastatic melanoma
The purpose of the study is to compare the clinical benefit and safety of volociximab Pharmacokinetics and mechanism of action will also be evaluated
The purpose of the study is to compare the clinical benefit and safety of volociximab Pharmacokinetics and mechanism of action will also be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None